Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
833 CRB-601, a selective integrin αvβ8-blocking antibody, prevents TGFβ activation, promotes immune cell remodeling, and exhibits potent antitumor activity
Compose a Response to This Article
Other responses
No responses have been published for this article.
